Effect of inhibition of fatty acid amide hydrolase on MPTP-induced dopaminergic neuronal damage;Efecto del inhibidor de amida hidrolasa de ácidos grasos en el daño neuronal dopaminérgico inducido por MPTP

Neurologia

Volumn 34, Issue 3, 2019, Pages 143-152

  Viveros Paredes, J M ^a   Gonzalez Castaneda R E ^a   Escalante Castaneda A ^a   Tejeda Martinez A R ^a   Castaneda Achutigui F ^a   Flores Soto, M E ^a,b  

^a UNIVERSITY OF GUADALAJARA   (Mexico)

^b INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

Author keywords

Cannabinoids; Neuroprotective; Parkinson's disease; Striatum; Substantia nigra

Indexed keywords

CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; TYROSINE 3 MONOOXYGENASE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AMIDASE; BENZAMIDE DERIVATIVE; CARBAMIC ACID DERIVATIVE; CYCLOHEXYL CARBAMIC ACID 3'-CARBAMOYLBIPHENYL-3-YL ESTER; FATTY-ACID AMIDE HYDROLASE; NEUROPROTECTIVE AGENT;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MICROGLIA; MOTOR COORDINATION; MOUSE; MPTP-INDUCED PARKINSONISM; NERVE CELL NECROSIS; NEUROMODULATION; NEUROPROTECTION; NONHUMAN; POLE TEST; STRIDE LENGTH; SUBSTANTIA NIGRA PARS COMPACTA; TREATMENT DURATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECT; MALE; METABOLISM; MOTOR PERFORMANCE; PARKINSON DISEASE; PATHOLOGY; SUBSTANTIA NIGRA;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AMIDOHYDROLASES; ANIMALS; BENZAMIDES; CARBAMATES; DISEASE MODELS, ANIMAL; DOPAMINERGIC NEURONS; MALE; MICE; MICE, INBRED C57BL; MOTOR SKILLS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 85009357387     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2016.11.008     Document Type: Article

References (34)

1. Nolan, Y., Sullivan, A., Toulouse, A., Parkinson's disease in the nuclear age of neuroinflammation. Trends Mol Med. 19 (2013), 187–196.
2. Franco, R., Fernandez, D., Alternatively activated microglia and macrophages in the central nervous system. Prog Neurobiol. 131 (2015), 65–86.
3. Nagatsu, T., Sawada, M., Inflammatory process in Parkinson's disease: Role for cytokines. Curr Pharm Des. 11 (2005), 999–1016.
4. Sawada, M., Imamura, K., Nagatsu, T., Role of cytokines in inflammatory process in Parkinson's disease. J Neural Transm Suppl., 2006, 373–381.
5. McGeer, E.G., McGeer, P.L., The role of anti-inflammatory agents in Parkinson's disease. CNS Drugs. 21 (2007), 789–797.
6. Murer, M.G., Raisman-Vozari, R., Gershanik, O., Levodopa in Parkinson's disease: Neurotoxicity issue laid to rest?. Drug Saf. 21 (1999), 339–352.
7. Goetz, C.G., Poewe, W., Rascol, O., Sampaio, C., Evidence-based medical review update: Pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. 20 (2005), 523–539.
8. Dexter, D., Jenner, P., Parkinson disease: From pathology to molecular disease mechanisms. Free Radic. Biol. Med. 62 (2013), 132–144.
9. Carrier, E.J., Kearn, C.S., Barkmeier, A.J., Breese, N.M., Yang, W., Nithipatikom, K., et al. Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism. Mol Pharmacol. 65 (2004), 999–1007.
10. Saario, S.M., Savinainen, J.R., Laitinen, J.T., Jarvinen, T., Niemi, R., Monoglyceride lipase-like enzymatic activity is responsible for hydrolysis of 2-arachidonoylglycerol in rat cerebellar membranes. Biochem Pharmacol. 67 (2004), 1381–1387.
11. Han, B., Wright, R., Kirchhoff, A., Chester, J., Cooper, B., Davisson, J., et al. Quantitative LC–MS/MS analysis of arachidonoyl amino acids in mouse brain with treatment of FAAH inhibitor. Anal Biochem. 423 (2013), 74–81.
12. Ativie, F., Albayram, O., Bach, K., Pradier, B., Zimmer, A., Bilkei-Gorzo, A., Enhanced microglial activity in FAAH–/– animals. Life Sciences. 138 (2015), 52–56.
13. Hermanson, J., Hartley, D., Gamble, J., Brown, N., Shonesy, B., Kingsley, P., et al. Substrate-selective COX-2 inhibition decreases anxiety via endocannabinoid activation. Nat Neurosci. 16 (2013), 1291–1298.
14. Avila-Costa, M.R., Ordoñez-Librado, J.L., Anaya-Martínez, V., Sánchez-Betancourt, J., Inhalación de manganeso como modelo experimental de la enfermedad de Parkinson. Mensaje Bioquímico. 37 (2013), 140–159.
15. Fernagut, P., Diguet, E., Labattu, B., Tison, F., A simple method to measure stride length as an index of nigrostriatal dysfunction in mice. J Neurosci Methods. 113 (2002), 123–130.
16. Matsuura, K., Kabuto, H., Makino, H., Ogawa, N., Pole test is a useful method for evaluating the mouse movement disorder caused by striatal dopamine depletion. J Neurosci Methods. 73 (1997), 45–48.
17. Paxinos, G., Franklin, K.B.J., The mouse brain in stereotaxic coordinates. 2. 2001, Academic, San Diego, CA.
18. Tieu, K.A., Guide to Neurotoxic Animal Models of Parkinson's disease. Cold Spring Harb Perspect Med., 1, 2011 1a009316.
19. Russo, R., loVerme, J., la Rana, G., Compton, T., Parrott, J., The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3′-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice. J Pharmacol Exp Ther. 322 (2007), 236–242.
20. Mclaughlin, J., Gobbi, G., Cannabinoids and emotionality: A neuroanatomical perspective. Neuroscience. 204 (2012), 134–144.
21. Kregiel, J., Malek, N., Popik, P., Starowicz, K., Rygula, R., Anandamide mediates cognitive judgement bias in rats. Neuropharmacology. 101 (2016), 146–153.
22. Eisenstein, A., Clapper, R., Holmes, V., Piomelli, D., Hohmann, G., A role for 2-arachidonoylglycerol and endocannabinoid signaling in the locomotor response to novelty induced by olfactory bulbectomy. Pharm Res. 61 (2010), 419–429.
23. Pacher, P., Bátkai, S., Kunos, G., The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 58 (2006), 389–462.
24. Pisani, A., Fezza, F., Galati, S., Battista, N., Napolitano, S., Finazzi, A., et al. High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann Neurol. 57 (2005), 777–779.
25. Hwang, J., Adamson, C., Butler, D., Janero, R., Makriyannis, A., Bahr Ben, A., Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: A neuroprotective therapeutic modality. Life Sciences. 86 (2010), 615–623.
26. Pradhan, S., Andreasson, K., Commentary: Progressive inflammation as a contributing factor to early development of Parkinson's disease. Exp Neurol. 241 (2012), 148–155.
27. Ajami, B., Bennett, J.L., Krieger, C., Tetzlaff, W., Rossi, F.M., Local self-renewal can sustain CNS microglia maintenance and function throughout adult life. Nat Neurosci. 10 (2007), 1538–1543.
28. Hanisch, U.K., Kettenmann, H., Microglia: Active sensor and ver- satile effector cells in the normal and pathologic brain. Nat Neurosci. 10 (2007), 1387–1394.
29. McGeer, P.L., Itagaki, S., Akiyama, H., McGeer, E.G., Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol. 24 (1988), 574–576.
30. Sagredo, O., González, S., Aroyo, I., Pazos, M.R., Benito, C., Lastres-Becker, I., et al. Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease. Glia. 57 (2009), 1154–1167.
31. Gómez-Gálvez, Y., Palomo-Garo, C., Fernández-Ruiz, J., García, C., Potential of the cannabinoid CB(2) receptor as a pharmacological target against inflammation in Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry. 64 (2016), 200–208.
32. Ashton, J.C., Glass, M., The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr Neuropharmacol. 5 (2007), 73–80.
33. Murphy, N., Cowley, T., Blau, C., Dempsey, C., Noonan, J., Gowran, A., et al. The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation. J Neuroinflammation., 9, 2012, 79.
34. Tham, C., Whitaker, J., Luo, L., Webb, M., Inhibition of microglial fatty acid amide hydrolase modulates LPS stimulated release of inflammatory mediators. FEBS Letters. 581 (2007), 2899–2904.